biokine_amir

About Amir Caspi

This author has not yet filled in any details.
So far Amir Caspi has created 39 blog entries.

Biokine Therapeutics Announces Issuance of Chinese Patent covering the composition and use of novel chemokine binding polypeptides

Biokine Therapeutics Announces Issuance of Chinese Patent covering the composition and use of novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation, and cancer (BKT130 project).

June 30th, 2014|Pre-Clinical Programs|

BioLineRx Receives Approval to Commence Phase 1 Trial for Novel Stem Cell Mobilization Treatmen

BioLineRx Receives Approval to Commence Phase 1 Trial for Novel Stem Cell Mobilization Treatment

The phase 1 trial of BKT-140/BL-8040 is expected to begin in Q3 2014, with results expected in late 2014 or early 2015. BKT-140/BL-8040 is also in Phase 2 for AML, with results expected in early 2015.

June 16th, 2014|Clinical Program BL8040|

Biokine Therapeutics Announces Issuance of United States Patent covering the use of CXCR4 antagonist for wound healing

Biokine Therapeutics Announces Issuance of United States Patent covering the use of CXCR4 antagonist for wound healing and re-epithelialization (BKT170 Project).

April 12th, 2014|Pre-Clinical Programs|

Investigator-Initiated Study for Novel Chronic Myeloid Leukemia Treatment

BioLineRx Announces Investigator-Initiated Study for Novel Chronic Myeloid Leukemia Treatment

A phase 1/2 study will assess the effect of BKT-140/BL-8040 in combination with standard therapy.

April 10th, 2014|Clinical Program BL8040|

BioLineRx Announces Issuance of United States Patent

BioLineRx Announces Issuance of United States Patent Covering Use of BKT-140/BL-8040 in Immunotherapy

BKT-140/BL-8040 is currently undergoing a Phase 2 trial for acute myeloid leukemia (AML) and is expected to commence a Phase 1 trial in stem cell mobilization in Q2 2014.

March 13th, 2014|Clinical Program BL8040|

Positive Preclinical Results for Novel Treatment for Chronic Myeloid Leukemia

BioLineRx Announces Positive Preclinical Results for Novel Treatment for Chronic Myeloid Leukemia

BKT-140/BL-8040 study published in Molecular Cancer Therapeutics.

BKT-140/BL-8040 is currently undergoing a Phase 2 trial for acute myeloid leukemia (AML) and is expected to commence a Phase 1 trial in stem cell mobilization in Q2 2014; top-line results from both trials are expected in Q4 […]

February 12th, 2014|Clinical Program BL8040|

Biokine Therapeutics Announces Issuance of United States Patent

Biokine Therapeutics Announces Issuance of United States Patent covering the composition and use of novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation, and cancer (BKT130 project).

January 29th, 2014|Pre-Clinical Programs|

BioLineRx Receives Orphan Drug Designation for Novel Stem Cell Mobilization Treatment

BioLineRx Receives Orphan Drug Designation for Novel Stem Cell Mobilization Treatment

BKT-140/BL-8040 previously received Orphan Drug Designation for treatment of Acute Myeloid Leukemia.

BKT-140/BL-8040 is expected to commence Phase 1 trial in stem cell mobilization in Q2 2014, and top-line results are expected in H2 2014.

January 23rd, 2014|Clinical Program BL8040|

BioLineRx Announces Regulatory Submission for Novel Stem Cell Mobilization Treatment

BioLineRx Announces Regulatory Submission for Novel Stem Cell Mobilization Treatment

The phase 1 Trial of BKT-140/BL-8040 expected to begin in Q2 2014; top-line results expected in H2 2014

BKT-140/BL-8040 is also in Phase 2 for AML; top-line results expected in H2 2014

January 13th, 2014|Clinical Program BL8040|

European Patent issued covering the composition and use of novel chemokine

Biokine Therapeutics Announces Issuance of European Patent covering the composition and use of novel
chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation, and cancer (BKT130 project).

January 11th, 2014|Pre-Clinical Programs|